Shares of Reata Pharmaceuticals, Inc. (RETA) are gaining nearly 10% on Tuesday morning despite no stock-related statement from the company.
RETA is currently trading at $30.01, up $2.69 or 9.85%, on the Nasdaq. The stock has traded between $25.02 and $153.41 in the 52-week period. The stock has lost nearly 75% in that period.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
For comments and feedback contact: editorial@rttnews.com
Business News